Please login to the form below

Not currently logged in
Email:
Password:

Wilson Therapeutics

This page shows the latest Wilson Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal

The new deal adds to others made by Alexion this year, including the $855m acquisition of rare disease company Wilson Therapeutics in April and privately-held autoimmune disease specialists Syntimmune in

Latest news

  • Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion adds to pipeline with $1.2bn Syntimmune buy

    In the meantime, however, it’s also been adding to its earlier-stage pipeline and the Syntimmune acquisition comes a few months after it snapped up Swedish biotech Wilson Therapeutics for ... $855m, adding orally-active copper binder WTX-101 in phase

  • Abingworth raises $315m to expand hunt for promising biotechs Abingworth raises $315m to expand hunt for promising biotechs

    The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for ... Abingworth has shown it is prepared to back

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    $855m offer for rare disease company Wilson Therapeutics. ... Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial

  • mRNA - message received mRNA - message received

    Arcturus Therapeutics. thrombopoietin; alpha-1 antitrypsin replacment; cystic fibrosis; iron disorders. Tekmira, Arrowhead. ... Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

  • IGEM Therapeutics appoints Dr Tim Wilson as CEO IGEM Therapeutics appoints Dr Tim Wilson as CEO

    Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research. ... Wilson has worked for numerous private and public life science companies in the US and Europe at

  • Therachon strengthens management team Therachon strengthens management team

    He currently serves as chairman of Asceneuron, Complix and InteRNA, and as a non-executive director at Hansa Medical, Sobi, Wilson Therapeutics and Dutch Top Sector Life Sciences and Health.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics